Loading
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
Previous close
$0.5629
+$0.0062 · +1.11%
After-hours
$0.5926
+$0.0297 · +5.28%
Sep 10, 7:32 PM ET
Regular session · ET · Market data may be delayed.
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
Day range
Current $0.5629
52-week range
Current $0.5629
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
25
Expensive
Sentiment
39
Bearish
Risk
66
High Risk
Momentum
28
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
Day range
Current $0.5629
52-week range
Current $0.5629
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | 3.89M USD | 11.24M USD |
| Cost of goods sold | — | 259K USD | 303K USD | 2.56M USD | 4.1M USD |
| Gross profit | — | −259K USD | −303K USD | 1.33M USD | 7.14M USD |
| Research and development | 18.78M USD | 21.84M USD | 18.59M USD | 17.65M USD | 11.52M USD |
| Selling, general, and administrative | 23.63M USD | 18.34M USD | 20.26M USD | 65.04M USD | 105.06M USD |
| Operating expenses | 39.16M USD | 40.18M USD | 38.85M USD | 82.69M USD | 116.58M USD |
| Interest income | 1.14M USD | 2.06M USD | 2.71M USD | 664K USD | 104K USD |
| Interest expense | 3.28M USD | 5.78M USD | 5.81M USD | 7.27M USD | 8.38M USD |
| Depreciation and amortization | 317K USD | 259K USD | 303K USD | 860K USD | 2.27M USD |
| Operating income | −39.16M USD | −40.43M USD | −39.15M USD | −81.36M USD | −109.43M USD |
| Net income | −26.98M USD | −38.51M USD | −42.2M USD | −44.82M USD | −142.61M USD |
Company facts updated Sep 11, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$18.25
3142.14% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | May 11, 2026 | 1:50 | — | — |
Stock split | Oct 21, 2022 | 1:50 | — | — |
Stock split | Aug 26, 2022 | 2:1 | — | — |
Effective May 11, 2026
1:50
Effective Oct 21, 2022
1:50
Effective Aug 26, 2022
2:1
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
